GlassScriptPhysician profile
Kyle Walter Parton
NPI 1619321262
$2,015.83
in general payments reported to CMS, 2019-2025
20 companies · $754 in 2025
The $754 reported for 2025 was more than what 81% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $44.92 · 2022: $186 · 2023: $442 · 2024: $589 · 2025: $754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,785.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,785.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $636.68 | 2021-2025 | |
| Novo Nordisk INC | $612.41 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $234.47 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $159.73 | 2022-2025 | |
| Xeris Pharmaceuticals, INC. | $37.87 | 2023-2024 | Gvoke Hypopen |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $35.52 | 2024-2025 | Caplyta |
| Amgen INC. | $33.09 | 2024 | Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $30.25 | 2025 | Airsupra |
| Exact Sciences Corporation | $29.20 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $24.31 | 2023 | |
| Neurocrine Biosciences, INC. | $23.41 | 2023 | Ingrezza |
| Axsome Therapeutics, INC. | $22.96 | 2025 | Symbravo |
| Astellas Pharma US INC | $20.54 | 2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.79 | 2024 | Ofev |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.55 | 2024 | Xifaxan, Trulance |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $18.23 | 2025 | Arexvy, Shingrix |
| Phathom Pharmaceuticals, INC. | $17.77 | 2024 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $16.08 | 2022 | |
| Abbott Laboratories | $14.08 | 2024 | Freestyle Libre 3 |
| Genentech USA, INC. | $11.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Parton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.